The financial results were slightly better than we expected with disciplined cost management in R&D and SG&A. The main value of Epigenomics lies within the health economic value of its two main tests. We feel that investors are under appreciating the significant value to healthcare systems world-wide. The reimbursement is hinging on robust data and the demonstration of real cost savings. While the concept of avoiding metastatic liver and colon cancer by testing is clear, we believe. Thus, current trading levels represent an attractive value proposition over a two to three-year period.
